Görtz B, Roth J, Krähenmann A, de Krijger R R, Muletta-Feurer S, Rütimann K, Saremaslani P, Speel E J, Heitz P U, Komminoth P
Department of Pathology, University of Zurich, Switzerland.
Am J Pathol. 1999 Feb;154(2):429-36. doi: 10.1016/S0002-9440(10)65289-3.
Endocrine pancreatic tumors (EPT) and neuroendocrine tumors (NET) occur sporadically and rarely in association with multiple endocrine neoplasia type 1 (MEN1). We analyzed the frequency of allelic deletions and mutations of the recently identified MEN1 gene in 53 sporadic tumors including 30 EPT and 23 NET (carcinoids) of different locations and types. Allelic deletion of the MEN1 locus was identified in 18/49 (36.7%) tumors (13/30, 43.3% in EPT and 5/19, 26.3% in NET) and mutations of the MEN1 gene were present in 8/52 (15.3%) tumors (4/30 (13.3%) EPT and 4/22 (18.1%) NET). The somatic mutations were clustered in the 5' region of the coding sequence and most frequently encompassed missense mutations. All tumors with mutations exhibited a loss of the other allele and a wild-type sequence of the MEN1 gene in nontumorous DNA. In one additional patient with a NET of the lung and no clinical signs or history of MEN1, a 5178-9G-->A splice donor site mutation in intron 4 was identified in both the tumor and blood DNA, indicating the presence of a thus far unknown MEN1 syndrome. In most tumor groups the frequency of allelic deletions at 11q13 was 2 to 3 times higher than the frequency of identified MEN1 gene mutations. Some tumor types, including rare forms of EPT and NET of the duodenum and small intestine, exhibited mutations more frequently than other types. Furthermore, somatic mutations were not restricted to foregut tumors but were also detectable in a midgut tumor (15.2% versus 16.6%). Our data indicate that somatic MEN1 gene mutations contribute to a subset of sporadic EPT and NET, including midgut tumors. Because the frequency of mutations varies significantly among the investigated tumor subgroups and allelic deletions are 2 to 3 times more frequently observed, factors other than MEN1 gene inactivation, including other tumor-suppressor genes on 11q13, may also be involved in the tumorigenesis of these neoplasms.
内分泌胰腺肿瘤(EPT)和神经内分泌肿瘤(NET)多为散发性,很少与1型多发性内分泌腺瘤病(MEN1)相关。我们分析了53例散发性肿瘤中最近鉴定出的MEN1基因的等位基因缺失和突变频率,这些肿瘤包括30例EPT和23例不同部位和类型的NET(类癌)。在18/49(36.7%)的肿瘤中鉴定出MEN1基因座的等位基因缺失(13/30,EPT中为43.3%;5/19,NET中为26.3%),8/52(15.3%)的肿瘤存在MEN1基因突变(4/30(13.3%)EPT和4/22(18.1%)NET)。体细胞突变集中在编码序列的5'区域,最常见的是错义突变。所有有突变的肿瘤在非肿瘤性DNA中均表现出另一个等位基因的缺失和MEN1基因的野生型序列。在另外一名患有肺部NET且无MEN1临床体征或病史的患者中,在肿瘤和血液DNA中均鉴定出内含子4中的5178-9G→A剪接供体位点突变,表明存在一种迄今未知的MEN1综合征。在大多数肿瘤组中,11q13处等位基因缺失的频率比已鉴定的MEN1基因突变频率高2至3倍。一些肿瘤类型,包括十二指肠和小肠罕见形式的EPT和NET,比其他类型更频繁地出现突变。此外,体细胞突变不仅局限于前肠肿瘤,在中肠肿瘤中也可检测到(15.2%对16.6%)。我们的数据表明,体细胞MEN1基因突变促成了一部分散发性EPT和NET,包括中肠肿瘤。由于在所研究的肿瘤亚组中突变频率差异显著,且等位基因缺失的观察频率高2至3倍,除MEN1基因失活外的其他因素,包括11q13上的其他肿瘤抑制基因,也可能参与了这些肿瘤的发生。